The funds for Medicare and Social Security are running out and fast. Medicare funds are expected to dry out by 2026, a good three years before the previously-projected timeframe, while the deadline for the depletion of Social Security remains unchanged at 2034. Around 60-62 million people are dependent on Medicare and Social Security, and the average monthly payment for beneficiaries is close to $1,300.
Medicare and Social Security, which are financed from payroll taxes, are crucial in helping Americans concerning healthcare and general welfare. Medicare is facing difficulties from an increase in the number of recipients as well as burgeoning healthcare costs. The recent cut in taxes has also hit the system’s funding. In 2017, Medicare spending amounted to more than $700 billion.
Although the portion of Medicare that covers hospital and nursing care expenses is expected to run out by 2026, the other parts which cover outpatient costs and prescription drugs are not in any immediate danger as their funding includes monthly premiums and other sources of federal revenue. However, these are likely to see an increase in costs at that time.
To increase the funding for both programs, the government can either raise the taxes, reduce the benefits or do both. Either way, authorities believe it is absolutely necessary for the government to take action immediately so that there is enough time for the involved parties to make necessary adjustments and also to make sure enough funds are shored up to avoid any deficits.
Most Popular
United Parcel Service (UPS) seems on track to regain lost strength
Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic
IPO Alert: What to look for when Boundless Bio goes public
Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.
Nike (NKE) bets on innovation and partnerships to return to high growth
Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company